-
1.发明授权Lipidomic approaches to determining drug response phenotypes in cardiovascular disease 有权确定心血管疾病药物反应表型的脂质体方法公开(公告)号：US08137977B2
公开(公告)日：2012-03-20
申请号：US12257957
申请日：2008-10-24
申请人： Rima F. Kaddurah-Daouk , Michelle M. Wiest , Steven M. Watkins , Rebecca Ann Baillie , Madhumita Patnaik , K. Ranga Rama Krishnan , Richard M. Weinshilboum , Ronald M. Krauss
发明人： Rima F. Kaddurah-Daouk , Michelle M. Wiest , Steven M. Watkins , Rebecca Ann Baillie , Madhumita Patnaik , K. Ranga Rama Krishnan , Richard M. Weinshilboum , Ronald M. Krauss
CPC分类号： G01N33/92 , G01N2800/32 , G01N2800/52
摘要： The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.
摘要翻译： 本发明涉及脂质组学对于诸如心血管疾病之类的病症的他汀类药物治疗的应用。 因此，本发明尤其提供了一种通过在开始治疗方案之后从哺乳动物受试者获得样品的脂质谱，将脂质谱与对他汀类药物治疗方案的阳性或阴性反应相关的方法; 并将样品中的脂质谱与对治疗方案的阳性或阴性反应相关联。 本发明还提供了一种通过在开始治疗方案之前从哺乳动物受试者获得样品的脂质分布来将脂质谱与对他汀类药物治疗方案的阳性或阴性反应相关的方法; 并将样品中的脂质谱与对治疗方案的阳性或阴性反应相关联。
-
公开(公告)号：US08637321B2
公开(公告)日：2014-01-28
申请号：US12091213
申请日：2006-10-12
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2405/00 , G01N2405/04 , G01N2800/30 , G01N2800/302
摘要： The present invention has utilized the power of lipidomics to profile lipid metabolites and to characterize changes in lipid metabolism as they relate to CNS disorders. Lipidomic signatures can guide the development of diagnostic, prognostic and surrogate markers for CNS disorders; identification of new targets for drug design based on highlighted perturbed pathways; stratify patients with CNS disorders as to which pathways are impaired, and facilitate the determination of which patients with CNS disorders are candidates for a particular therapy, i.e. provide the tools for a personalized approach to therapy; identify which patients are responding or are developing side effects to a treatment; design of modified antipsychotics that have less metabolic side effects and enhanced activity; overcome the lag phase in response to some treatments; and find better combination therapies for CNS disorders that target the pathways that are impaired (e.g., impairments in lipid and/or carbohydrate metabolism).
摘要翻译： 本发明利用脂质组学的功能来分析脂质代谢物并描述它们与CNS疾病相关的脂质代谢变化。 脂质体标记可以指导中枢神经系统疾病的诊断，预后和替代标志物的发展; 基于突出的扰动途径确定药物设计的新目标; 分层中枢神经系统疾病患者，哪些途径受损，并有助于确定哪些中枢神经系统疾病患者是特定治疗的候选者，即为个体化治疗方法提供工具; 确定哪些患者正在应对或正在对治疗产生副作用; 具有较少代谢副作用和增强活性的改良抗精神病药的设计; 克服一些治疗响应的滞后期; 并找到针对受损途径（例如脂质和/或碳水化合物代谢障碍）的CNS疾病的更好的组合疗法。
-
公开(公告)号：US20090305323A1
公开(公告)日：2009-12-10
申请号：US12091213
申请日：2006-10-12
IPC分类号： C12Q1/02
CPC分类号： G01N33/92 , G01N2405/00 , G01N2405/04 , G01N2800/30 , G01N2800/302
摘要： The present invention has utilized the power of lipidomics to profile lipid metabolites and to characterize changes in lipid metabolism as they relate to CNS disorders. Lipidomic signatures can guide the development of diagnostic, prognostic and surrogate markers for CNS disorders; identification of new targets for drug design based on highlighted perturbed pathways; stratify patients with CNS disorders as to which pathways are impaired, and facilitate the determination of which patients with CNS disorders are candidates for a particular therapy, i.e. provide the tools for a personalized approach to therapy; identify which patients are responding or are developing side effects to a treatment; design of modified antipsychotics that have less metabolic side effects and enhanced activity; overcome the lag phase in response to some treatments; and find better combination therapies for CNS disorders that target the pathways that are impaired (e.g., impairments in lipid and/or carbohydrate metabolism).
摘要翻译： 本发明利用脂质组学的功能来分析脂质代谢物并描述它们与CNS疾病相关的脂质代谢变化。 脂质体标记可以指导中枢神经系统疾病的诊断，预后和替代标志物的发展; 基于突出的扰动途径确定药物设计的新目标; 分层中枢神经系统疾病患者，哪些途径受损，并有助于确定哪些中枢神经系统疾病患者是特定治疗的候选者，即为个体化治疗方法提供工具; 确定哪些患者正在应对或正在对治疗产生副作用; 具有较少代谢副作用和增强活性的改良抗精神病药的设计; 克服一些治疗响应的滞后期; 并找到针对受损途径（例如脂质和/或碳水化合物代谢障碍）的CNS疾病的更好的组合疗法。
-
-
搜索结果
3 条记录 (耗时 0.036 秒)
